IDEXX Laboratories, Inc. — FY2016 Form 10-K Summary
Business context and reporting period
IDEXX develops diagnostic products, services and information-management solutions for veterinary, water-quality, livestock, poultry and dairy markets, with a smaller human point-of-care diagnostics business. The filing covers the fiscal year ended December 31, 2016; quarterly data includes the three months ended December 31, 2016.
The company operates through Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. Approximately 39% of full-year revenue came from customers outside the United States.
Key financial metrics
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Revenue | $1.775 billion | $1.602 billion | 10.8% |
| Organic revenue growth | 11.4% | 13.4% | Down 2.0 pts |
| Gross profit | $975.4 million | $890.3 million | 9.6% |
| Gross margin | 54.9% | 55.6% | Down 70 bps |
| Operating income | $350.2 million | $299.9 million | 16.8% |
| Operating margin | 19.7% | 18.7% | Up 100 bps |
| Net income attributable to IDEXX stockholders | $222.0 million | $192.1 million | 15.6% |
| Diluted EPS | $2.44 | $2.05 | 19.0% |
| Operating cash flow | $334.6 million | $216.4 million | 54.6% |
Implied FY2016 net margin was approximately 12.5% and operating cash flow was approximately 18.8% of revenue. Research and development expense was $101.1 million, or 5.7% of revenue. Recurring diagnostic revenue represented approximately 72% of consolidated revenue.
Fourth-quarter 2016 results
| Metric | Q4 2016 | Q4 2015 |
|---|---|---|
| Revenue | $443.0 million | $399.7 million |
| Gross profit | $240.6 million | $217.7 million |
| Operating income | $83.8 million | $66.9 million |
| Net income attributable to stockholders | $52.4 million | $44.3 million |
| Diluted EPS | $0.58 | $0.48 |
Segment performance and material changes
- CAG: Revenue increased 12.3% to $1.523 billion, with organic growth of 12.6%. Recurring diagnostic revenue grew 11.7%, including 13.9% growth in VetLab consumables and 13.5% growth in reference laboratory services. CAG operating income increased 29.2% to $301.3 million, and margin expanded to 19.8% from 17.2%.
- Water: Revenue increased 6.9% to $103.6 million, with organic growth of 8.7%. Growth reflected Colilert products, Quanti-Tray Sealer PLUS placements, project orders and cryptosporidium-related demand.
- LPD: Revenue declined 0.5% to $126.5 million, although organic growth was 1.1%. Western European bovine disease-eradication programs and lower worldwide milk prices pressured results. Operating income declined 30.4% to $18.9 million and margin fell to 15.0% from 21.4%.
- Other: Revenue increased 5.0% to $22.7 million, primarily from royalty revenue, partly offset by lower OPTI Medical sales. The company discontinued development of a new human point-of-care platform and recorded a $2.2 million non-cash intangible impairment; related intangibles were fully written off.
- New products and platforms included the SediVue Dx urine sediment analyzer, launched in North America in April 2016 and in the U.K. and Australia in Q4; the ImageVue DR50 imaging system; Legiolert water testing; and a cattle pregnancy test. SediVue Dx generated $24.2 million of 2016 instrument and pay-per-run revenue.
- The company continued its shift toward subscription-based veterinary software and services, while Catalyst and ProCyte instrument placements expanded the installed base and supported recurring consumable revenue.
Liquidity, debt and capital allocation
| Balance-sheet metric | December 31, 2016 |
|---|---|
| Cash and cash equivalents | $154.9 million |
| Marketable securities | $236.9 million |
| Total cash, equivalents and securities | $391.8 million |
| Revolving credit facility outstanding | $611.0 million |
| Long-term debt | $593.1 million |
| Total debt | Approximately $1.204 billion |
| Net debt | $815.8 million |
| Credit-facility availability | Approximately $238 million |
| Working capital | $(89.0) million |
Management stated that cash, short-duration marketable securities, operating cash flow and committed borrowing capacity should fund operations and anticipated growth needs for at least the next twelve months. Gross debt to adjusted EBITDA was 2.66x and net debt to adjusted EBITDA was 1.80x. The company was in compliance with its debt covenants.
Operating cash flow was $334.6 million. Capital expenditures were $64.8 million, and 2017 capital expenditures were estimated at approximately $90 million. The company repurchased 3.1 million shares for $313.1 million during 2016, with 3.7 million shares remaining under the authorization at year-end. IDEXX has never paid a cash dividend and stated it did not intend to pay one at that time.
Outlook, commentary and risks
- No specific consolidated revenue or earnings guidance is provided in the filing text. Management expects recurring diagnostic growth, new product adoption, international expansion and operating efficiencies to support performance.
- Management estimated that, under its 2017 currency assumptions, a stronger U.S. dollar would reduce 2017 revenue by approximately $26 million, operating profit by $8 million and diluted EPS by $0.06, including expected hedging benefits.
- Foreign exchange remains material: a 1% strengthening of the U.S. dollar was estimated to reduce revenue by approximately $7 million and operating income by approximately $3 million before incremental hedge gains.
- Principal risks include intense competition, veterinary customer consolidation and buying groups, reliance on sole- or single-source suppliers, manufacturing and biologic-product complexity, regulatory approvals, patent expiration and intellectual-property claims, cybersecurity and data-privacy requirements, international operations, economic weakness, tax audits and debt-covenant or refinancing risk.
- The company held approximately $387.0 million of cash, equivalents and marketable securities outside the United States. Repatriation could result in additional tax expense; no provision was recorded for certain potential repatriation taxes.
- Contractual cash obligations totaled approximately $991.6 million, including $753.0 million of long-term debt obligations, $57.9 million of operating leases and $179.2 million of purchase obligations.
- Contingent consideration liabilities could reach $6.4 million, of which $0.9 million was accrued. Ordinary-course legal proceedings were not expected by management to have a material effect, although unfavorable outcomes remain possible.
- Management and PricewaterhouseCoopers concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2016.
Important facts for investors to verify
- Whether CAG recurring revenue growth and high-margin consumable and reference-laboratory volumes remain durable as competition and veterinary customer consolidation increase.
- The sustainability of CAG margin expansion and the extent to which currency, pricing, hedging and product mix affect consolidated margins.
- LPD recovery prospects, particularly exposure to disease-eradication programs, milk prices and international markets.
- Adoption, utilization and recurring economics of SediVue Dx, Catalyst, ProCyte, subscription software and other recently launched products.
- Debt repayment capacity, variable-rate exposure, covenant headroom and the balance between share repurchases, capital spending and debt reduction.
- The impact of foreign exchange movements, unrecognized tax benefits of approximately $18.5 million and potential taxes on foreign earnings.
- Execution of the estimated 2017 capital plan and the impact of the new revenue-recognition, lease and share-based-payment accounting standards.